Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: To evaluate the performance of artificial intelligence (AI) systems embedded in a mobile, handheld retinal camera, with a single retinal image protocol, in detecting both diabetic retinopathy (DR) and more-than-mild diabetic retinopathy (mtmDR).

Design: Multicenter cross-sectional diagnostic study, conducted at 3 diabetes care and eye care facilities.

Participants: A total of 327 individuals with diabetes mellitus (type 1 or type 2) underwent a retinal imaging protocol enabling expert reading and automated analysis.

Methods: Participants underwent fundus photographs using a portable retinal camera (Phelcom Eyer). The captured images were automatically analyzed by deep learning algorithms retinal alteration score (RAS) and diabetic retinopathy alteration score (DRAS), consisting of convolutional neural networks trained on EyePACS data sets and fine-tuned using data sets of portable device fundus images. The ground truth was the classification of DR corresponding to adjudicated expert reading, performed by 3 certified ophthalmologists.

Main Outcome Measures: Primary outcome measures included the sensitivity and specificity of the AI system in detecting DR and/or mtmDR using a single-field, macula-centered fundus photograph for each eye, compared with a rigorous clinical reference standard comprising the reading center grading of 2-field imaging protocol using the International Classification of Diabetic Retinopathy severity scale.

Results: Of 327 analyzed patients (mean age, 57.0 ± 16.8 years; mean diabetes duration, 16.3 ± 9.7 years), 307 completed the study protocol. Sensitivity and specificity of the AI system were high in detecting any DR with DRAS (sensitivity, 90.48% [95% confidence interval (CI), 84.99%-94.46%]; specificity, 90.65% [95% CI, 84.54%-94.93%]) and mtmDR with the combination of RAS and DRAS (sensitivity, 90.23% [95% CI, 83.87%-94.69%]; specificity, 85.06% [95% CI, 78.88%-90.00%]). The area under the receiver operating characteristic curve was 0.95 for any DR and 0.89 for mtmDR.

Conclusions: This study showed a high accuracy for the detection of DR in different levels of severity with a single retinal photo per eye in an all-in-one solution, composed of a portable retinal camera powered by AI. Such a strategy holds great potential for increasing coverage rates of screening programs, contributing to prevention of avoidable blindness.

Financial Disclosures: F.K.M. is a medical consultant for Phelcom Technologies. J.A.S. is Chief Executive Officer and proprietary of Phelcom Technologies. D.L. is Chief Technology Officer and proprietary of Phelcom Technologies. P.V.P. is an employee at Phelcom Technologies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11060947PMC
http://dx.doi.org/10.1016/j.xops.2024.100481DOI Listing

Publication Analysis

Top Keywords

diabetic retinopathy
20
phelcom technologies
16
retinal camera
12
single retinal
8
imaging protocol
8
expert reading
8
portable retinal
8
alteration score
8
data sets
8
outcome measures
8

Similar Publications

Background: Diabetic retinopathy (DR) is a major complication of diabetes mellitus, characterised by retinal vasculopathy and oxidative stress. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated cardiovascular benefits but has also been associated with mixed effects on DR progression. This study investigates the potential of semaglutide to attenuate DR progression by ameliorating retinal vasculopathy and oxidative stress in both in vivo and in vitro models.

View Article and Find Full Text PDF

Objectives: To investigate whether quantitative retinal markers, derived from multimodal retinal imaging, are associated with increased risk of mortality among individuals with proliferative diabetic retinopathy (PDR), the most severe form of diabetic retinopathy.

Design: Longitudinal retrospective cohort analysis.

Setting: This study was nested within the AlzEye cohort, which links longitudinal multimodal retinal imaging data routinely collected from a large tertiary ophthalmic institution in London, UK, with nationally held hospital admissions data across England.

View Article and Find Full Text PDF

ADAMTS13-mediated angiogenesis by PLK-1/Ang-2 is independent of VEGF in diabetic retinopathy.

Exp Eye Res

September 2025

Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Hongkou District, Shanghai, 200080, China. Electronic address:

Purpose: A disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) has been found to increase and to be associated with diabetic retinopathy (DR). The study aimed to identify the role of ADAMTS13 in the pathogenesis of angiogenesis in DR.

Methods: ADAMTS13 expression was evaluated in human retinal microvascular endothelial cells (HRMVECs), vitreous sample from patients with proliferative DR and diabetic mice model using western blot, real time-quantitative PCR, immunofluorescence and ELISA.

View Article and Find Full Text PDF

PM: A new prompting multi-modal model paradigm for few-shot medical image classification.

Comput Methods Programs Biomed

September 2025

Key Laboratory of Social Computing and Cognitive Intelligence (Ministry of Education), Dalian University of Technology, Dalian, 116024, China; School of Computer Science and Technology, Dalian University of Technology, Dalian, 116024, China. Electronic address:

Background And Objective: Few-shot learning has emerged as a key technological solution to address challenges such as limited data and the difficulty of acquiring annotations in medical image classification. However, relying solely on a single image modality is insufficient to capture conceptual categories. Therefore, medical image classification requires a comprehensive approach to capture conceptual category information that aids in the interpretation of image content.

View Article and Find Full Text PDF

Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, with the affected population projected to reach 270 million by 2045. Our study analyzed 2 434 interventional trials registered between 2007 and 2024 in the Informa Pharma Intelligence database and found that anti-VEGF agents dominate the therapeutic landscape-bevacizumab represents 24.0 % of studies, ranibizumab 15.

View Article and Find Full Text PDF